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Abstract
The present study aimed to validate ThermoFisher’s (Thermo Fisher Scientiﬁc, Runcorn, Cheshire, UK) Papspin (PS) for human papillo-
mavirus (HPV) testing by in-house PCR and by the Hybrid Capture II (HC2) assay and to compare the results with those obtained using
Specimen Transport Medium (STM) (Digene Diagnostics, Gaithersburg, MD, USA). Forty-ﬁve patients underwent conization for known
lesions ranging from atypical squamous cells of undetermined signiﬁcance (ASC-US) with high-risk HPV (hr-HPV) to high-grade squa-
mous intraepithelial lesion (H-SIL/CIN2+) or adenocarcinoma. Two negative controls were included: one patient with post-menopausal
bleeding and another from whom an inﬂammatory cervical sample was taken without conization. Prior to conization, a gynaecologist
collected two cervical samples, ﬁxed in PS or STM, from each patient. All but four cases were tested for panHPV (GP5+/GP6+) and
speciﬁc hr-HPV subtypes (HPV16, 18, 31,33) by PCR using both media and all were processed for HC2. This study demonstrates that
both HPV detection techniques work with PS, showing a speciﬁcity of 78.3% for HC2 and 92.8% for PCR compared to 83.8% for HC2
and 92% for PCR using STM. The efﬁcacy of detecting HPV in PS-preserved H-SIL/CIN2+ was very high (96% for PCR using PS and
86% for HC2 using PS), which was in the same range as for PCR using STM, and which was only slightly lower than for HC2 using STM
(96% and 89%, respectively). The differences were not statistically signiﬁcant. It is concluded that ThermoFisher’s PS is a valid liquid-
based cytology medium for cervical samples, convenient for HPV testing by PCR with GP5+/GP6+ primers and by the HC2 assay.
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Introduction
Cervical cancer is the second most common cause of death
from cancer in women worldwide [1]. Human papillomavirus
(HPV), when integrated in human DNA, is responsible for
most of the cervical neoplasms [2].
The keystone for preventing cervical cancer development
and detecting preneoplastic lesions is the Pap smear taken
on a regular basis [3]. It has been shown that liquid-based
cytology (LBC) has a sensitivity and speciﬁcity for detecting
high-grade cervical intraepithelial neoplasia similar to the
conventional Pap smear. However, the quality of preparation,
more rapid microscopic interpretation, and the possibility to
add molecular testing explains the fact that LBC has received
much attention [4]. In recent years, different techniques have
emerged, allowing the detection of the presence of HPV in
LBC. These techniques have been advocated, in the Euro-
pean and French guidelines [5,6], as adjuncts to cytological
analysis for the triage of lesions associated with atypical
squamous cells of undetermined signiﬁcance (ASC-US), atypi-
cal squamous cells, without the possibility of excluding a
high-grade intraepithelial lesion (ASC-H) and atypical glandu-
lar cells (AGC).
The American Society for Colposcopy and Cervical Pathol-
ogy has also updated their guidelines for HPV testing the
follow-up of high-grade intraepithelial lesions (H-SIL) after
treatment [7,8]. These recommendations are underlined in
two meta-analyses by Arbyn et al. [9,10] who showed that
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there is sufﬁcient evidence in the literature to prefer HPV
testing over repeat performance of Pap smears in the triage of
women with atypical cytology and in the surveillance after
treatment of cervical intraepithelial neoplasia (CIN) lesions
[9,10].
The most reliable DNA-based tests now available are the
consensus primer PCR assay and the Hybrid Capture II
(HC2) microtitre assay, which is a hybridization technique
using a single-stranded RNA probe and viral DNA without
previous ampliﬁcation [Hybrid Capture II; Digene Diagnos-
tics, Gaithersburg, MD, USA] [11–13]. These techniques
have been validated using the Surepath (Tripath Care Tech-
nologies, Burlington, NC, USA) [14,15] and Thinprep (Cytyc,
Boxborough, MA, USA) [12] systems, but only the latter has
been Food and Drug Administration approved for HC2 test-
ing since 2002.
The present study aimed to validate ThermoFisher’s Pap-
spin (PS) for HPV testing by in-house PCR using GP5+/GP6+
primers and HC2 to compare the results with those
obtained using Specimen Transport Medium (STM) (Digene
Diagnostics, Gaithersburg, MD, USA).
Materials and Methods
Study group
The study involved 47 women (mean age, 40 years; range,
19–66 years). Forty-six of them underwent conization. One
woman had only a cervical sample taken. In 45 cases, coniza-
tion was planned for cytological and/or histological diagnoses,
ranging from ASC-US with PCR-positive high-risk HPV
(hr-HPV) to high-grade squamous intraepithelial lesion (H-SIL/
CIN2+), AGC or adenocarcinoma.
The study included two negative controls, one of whom
underwent conization for postmenopausal bleeding after a
laparoscopically assisted supracervical procedure; an inﬂam-
matory cervical sample was taken from the other without
conization.
Just before the conization procedure, all women had two
Pap smears taken, one using a Cervex brush (Rovers Medical
Devices, Oss, the Netherlands) that was immediately immersed
in ThermoFisher’s PS, and the other taken at random before
or after the PS sample, using the sampling kit for the HC2 assay
(STM).
Both specimens from each patient were split in our labora-
tory (Cliniques universitaires St Luc, UCL, Brussels) in order
to obtain material for in-house PCR and HC2 analysis in both
media. HC2 analysis was carried out in another university hos-
pital [Universite´ de Lie´ge (ULg)] for technical reasons. The
material was kept no longer than 2 weeks at room tempera-
ture before analysis, as speciﬁed by the manufacturers.
For each patient, a monolayer Pap smear was obtained by
cytocentrifuging up to 4 mL of PS for cytological analysis
after Papanicolaou staining. All patients had a classical
work-up of their conization specimens after formalin ﬁxation
for 24 h. All four quadrants were included separately in par-
afﬁn-blocks, cut into 5-lm thick slices and stained with hae-
matoxylin and eosin. Conization specimens were analysed
independently of the cervical samples and the results of
cytology and histology were pooled for ﬁnal analysis.
All but four cases were tested for Pan HPV (GP5+/GP6+)
and for speciﬁc hr-HPV genotypes (HPV 16, 18, 31, 33) by
PCR in both media and all were processed for HC2. PCR
and HC2 results were recorded independently.
PCR technique
DNA from cell suspensions was extracted (QIAMP DNA mini
Kit; Qiagen, Valencia, CA, USA) according to the manufac-
turer’s instructions using 5 mL of PS and 1 mL of STM, respec-
tively. PCRs were performed with a 9700 thermocycler (PE
Applied Biosystems, Norwalk, CT, USA) in a 25-lL reaction
volume containing 1· PCR buffer, 3.5 mM MgCl2, 1 U enzyme
(Taq Polymerase; Applied Biosystems, Branchburg, NJ, USA),
0.25 mM dNTP (Roche Diagnostics, Mannheim, Germany),
sense primers labelled with a ﬂuorochrome (FAM or HEX)
and antisense primers [11], both at 10 lM, and ﬁnally 5 lL of
sample DNA. Table 1 gives the details of the technique for
GP5+/GP6+ HPV testing and HPV 16, 18, 31, 33 genotyping.
PCR ampliﬁcation was based on a 40-cycle thermal proﬁle
using denaturation and extension steps as described in
TABLE 1. Sequences of oligonucleotide primers, reaction conditions for PCR and PCR product characteristics
HPV
subtype
Gene
(DNA)
region Sense primer 5¢- to 3¢ Antisense primer 5¢- to 3¢
Annealing
C (s)
Extension
C (s) Dye
Size
(bp)
GP5+/GP6+ L1 gAAAAATAAACTgTAAATCATATTC TTTgTTACTgTggTAgATACTAC 40 (120) 72 (90) FAM 140
HPV-16 L1 CAAAATTCCAgTCCTCCA A gCACAgggCCACAATAATgg 55 (45) 72 (60) FAM 270
HPV-18 E7 AAgAAAAcgATgAAATAgATggA ggCTTCACACTTACAACACA 55 (45) 72 (60) HEX 102
HPV-31 E7 TTACCCgACAgCTCAgATgA CACACgATTCCAAATgAgCC 52 (45) 72 (60) FAM 190
HPV-33 E7 ATgAgAggACACAagCCAACg T TgTgCCCATAAgTagTTgCT 52 (45) 72 (60) HEX 260
HPV, human papillomavirus.
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Table 1. Fluorescent PCR products were analysed by capillary
electrophoreses and optical detection of ﬂuorescence
(GenScan; Applied Biosystems, Foster City, CA, USA). Molecu-
lar weight, ﬂuorescence colour (FAM or HEX) and intensity of
the amplicon were used for PCR interpretation.
GP5+/GP6+ PCR is capable of recognizing 14 hr-HPV sub-
types (16,18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68)
and six low-risk HPV subtypes (6, 11, 40, 42, 43, 44) [16].
HC2 assay
The HC2 assay was performed on the same collected cellu-
lar material as for the PCRs in order to test for the pres-
ence of DNA from 13 high-risk HPV types (16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59 and 68), comprising the same
types as those detected by the GP5+/GP6+ PCR method
with the exception of HPV 66. The target DNA was dena-
tured and hybridized with the cocktail of viral RNA probes.
The resultant DNA:RNA hybrids were captured on a micro-
plate coated with antibodies speciﬁc for DNA:RNA hybrids.
After signal detection with antibodies conjugated with alka-
line phosphatase and substrate, the light emitted was mea-
sured in a luminometer as the relative light units (RLU).
Samples were classiﬁed as positive for high-risk HPV if the
RLU reading was greater than 1.0 (equivalent to 1 pg HPV
DNA/mL).
Results
Forty-three patients underwent four HPV tests performed,
whereas four had no PCR analysis in STM because of a lack
of material.
Comparisons of HPV-detection techniques between the
different transport media were made concerning speciﬁcity,
sensitivity, positive predictive and negative predictive value,
for any abnormalities with a threshold for ASC-US/CIN1+
(Table 2).
Comparing the results of HC2 carried out in both media,
four discordant results were observed. Three were false
negative in PS, and one was false negative in STM. For PCRs,
there were two discordant results, with one negative PCR
and one positive PCR case in STM compared to PCR in PS.
Histological analysis conﬁrmed a CIN or a neoplastic glan-
dular lesion in 35 patients. In ﬁve patients, the conization
specimen was negative, but the cervical sample demonstrated
two ASC-US cases with hr-HPV, two with low-grade intra-
epithelial lesions (L-SIL) and one with H-SIL.
Seven cases showed no lesion in either the cervical sample
or the conization specimen. Two of these cases had a posi-
tive PCR (n = 2) and/or HC2 (n = 1) without any corre-
sponding cyto/histological lesion. In one case, the patient had
had a previous CIN 1-, panHPV-positive biopsy 2 months
prior to conization, whereas, in the other, the patient had
had a CIN 2 lesion diagnosed on a previous biopsy.
Apart from the two negative controls, two cases were
true negative. One concerned a patient with AGC-US seen
in several previous cervical samples without any histological
conﬁrmation, in which the corresponding conization speci-
men showed metaplastic changes in the endocervix. The sec-
ond case concerned reactive endocervical atypia in a woman
suspected to have had a L-SIL lesion in a previous cervical
sample and biopsy. In both cases, PCR and HC2 were nega-
tive, conﬁrming the absence of HPV infection. Finally, in one
case, no lesion could be found nor any sign of HPV infection,
although the patient had a CIN 2 lesion conﬁrmed by biopsy
1 month before.
The sensitivity of detection of H-SIL/CIN2+ lesions was
very high for all methods (96% for PCR in PS and STM, 86%
for HC2 in PS and 89% in STM; Table 3). All but one H-SIL/
CIN2+ lesion was detected by PCR-PS. All but three H-SIL/
CIN2+ lesions were identiﬁed by HC2-STM. Using Fisher’s
exact test (chi-square test), no statistically signiﬁcant difference
was observed between STM and PS whatever the technique
TABLE 2. Comparison of two human papillomavirus detec-
tion methods (HC2 and PCR) with different transport media
(STM and PS) using any abnormality (ASCUS/CIN1+) as
threshold
HC2-STM HC2-PS PCR-PS PCR-STM
n 47 43 47 43
Speciﬁcity 83.8% (31/37) 78.3% (29/37) 92.8% (39/42) 92% (35/38)
Sensitivity 100% (31/31) 100% (29/29) 100% (39/39) 100% (35/35)
PPV 100% (5/5) 100% (5/5) 100% (5/5) 100% (5/5)
NPV 41.6% (5/12) 35.7% (5/14) 62.5% (5/8) 62.5% (5/8)
HC2, Hybrid Capture II; STM, Digene Specimen Transport Medium; PS, Ther-
moFisher’s Papspin; PPV, positive predictive value; NPV, negative predictive
value.
TABLE 3. Detection rate of human papillomavirus infection
by ﬁnal diagnosis
HC2-STM HC2-PS PCR-PS PCR-STM
H-SIL 25/28 24/28 27/28 24/25
AIS 1/1 0/1 1/1 1/1
L-SIL 2/9 2/9 7/9 6/8
ASC-US 2/2 2/2 2/2 2/2
Negative 1/5 1/5 2/5 2/5
Negative control 0/2 0/2 0/2 0/2
Total 47 47 47 43
HC2, Hybrid Capture 2; STM, Digene Specimen Transport Medium; PS, Ther-
moFisher’s Papspin; H-SIL, high-grade intra-epithelial lesion; AIS, Adenocarci-
noma in situ; L-SIL, low-grade intraepithelial lesion; ASC-US, atypical squamous
cells of undetermined signiﬁcance.
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used (p 0.163), when the results were compared with a
threshold for H-SIL/CIN2+.
Twenty-one patients of the study group had GP5+/GP6+
PCR HPV testing prior to conization. Eleven of these were
found to have the same subtype(s) in both analyses. Of the
others, all but one had at least one identical subtype in the
subsequent analysis compared to the ﬁrst genotyping.
Discussion
ThermoFisher’s PS is a liquid-based method, which has been
described as a valid technique for the diagnosis of abnormal
uterine cervix cytology samples compared to the classical
Pap smear [17]. The present study aimed to validate
in-house GP5+/GP6+ PCR and HC2 testing in this techni-
que´s medium compared to STM, which is the reference stan-
dard transport medium for HC2, in order to be able to
apply these techniques using a liquid-based medium different
from those previously studied (Surepath and Thinprep).
The PCR technique is considered as the most sensitive
method for the detection of HPV DNA in clinical specimens
[11]. HC2 is a second-generation commercial test for HPV
detection, which has been correlated with detection of HPV-
DNA sequences by type-speciﬁc or consensus PCR [18–20].
The present study involved a limited number of cases, but
emphasized samples from women with known cervical dis-
ease. These women would be expected to have a higher viral
load than those without disease. One might therefore accept
that the number of patients is sufﬁcient for validation of
ThermoFisher’s PS using in-house GP5+/GP6+ PCR and the
HC2 assay for HPV testing compared to STM.
The present study demonstrates that both HPV detection
techniques work with PS, showing a speciﬁcity ranging from
78.3% for HC2 to 92.8% for PCR, with a high detection rate
of H-SIL/CIN2+ (85.7% for HC2 and 96.4% for PCR). These
results are similar to those published previously, ranging
from 82.6% to 93% for HC2 and from 96% to 100% for PCR
using various media [14,19–25].
In STM, PCR showed also a higher detection rate of
H-SIL/CIN2+ lesions than HC2 (92% vs. 83.8%), in accor-
dance with a previous study [11]. The detection rate of
L-SIL/CIN1 lesions (2/9 by HC2 vs. 6/8 by PCR) is also lower
because of the absence of low-risk genotypes in the HC2-kit.
Both HC2-positive L-SIL cases were hr-HPV-positive by PCR
(HPV 16 in one case and HPV 31, 33 in the other case).
In comparison with histology, six false-negative cases were
observed by HC2 using both media, including three H-SIL
and three L-SIL cases (all hr-HPV positive by PCR, two
HPV16 and one HPV31, 33). These results may be explained
by a very low level of HPV detection by PCR (in three cases)
[16] or by the absence of HPV66 detection by HC2 (in two
cases). The last, a HPV16-positive L-SIL/CIN1 case, is proba-
bly the result of a split-sample bias because only PCR in STM
was positive.
In addition, we observed four cases in which HC2 was
either negative in PS (n = 3) or in STM (n = 1) alone, which is
also probably the result of a split-sample bias, underlined by
the fact that, in all four negative samples, low quantities of
HPV DNA were present, ranging from 0.43 to 0.72 RLU [16].
In 40 of the 47 cases studied, cyto/histological diagnosis
correlated well with the HPV testing results. Of the remain-
ing seven cases, four were negative (i.e. the two negative
controls and two cases of reactive endocervical lesions).
In two cases, PCR and/or HC2 were positive without cyto/
histological abnormalities. In both cases, PCR (n = 2, one in
PS alone, one in both media) and/or HC2 (n = 1, in both
media) were positive, without any corresponding cyto/histo-
logical lesion. In both cases, the HPV test result supported a
persistent HPV infection even without cyto/histological
proof; whether these were subclinical infections or lesions
missed by cytology and histology is difﬁcult to assess [26,27].
The last case concerned a 26-year-old patient who had had
an H-SIL/CIN2 lesion conﬁrmed by biopsy, in whom no lesion
or any sign of HPV infection was found. This could be the result
of the spontaneous disappearance of the lesion, a fact previ-
ously described in women younger than 30 years of age [28].
In conclusion, ThermoFisher’s PS appears to be a valid
liquid-based cytology medium for cervical samples that are
convenient for HPV testing by PCR with GP5+/GP6+ primers
and the HC2 assay.
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